HLA loss variants of a B27+ lymphoblastoid cell line: genetic and cellular characterization

Specific-locus mutations induced in eukaryotes (especially mammalian cells) by radiation and chemicals: a perspective

In the course of discovering the first mutagen (X-rays) just over 60 years ago, Herman J. Muller asked whether X-rays induced single-gene mutations and/or chromosomal (multiple-gene) mutations. To a large extent, his question has set the agenda for mutagenesis research ever since. We explore historically the answers to this question, with special emphasis on recent developments in the field of mammalian cell mutagenesis. Studies indicate that ionizing radiation and many chemical mutagens/carcinogens induce both gene and chromosomal mutations; however, only certain genetic systems permit the recovery and analysis of both classes of mutations. Few chemical mutagens induce only gene mutations in mammalian cells; instead, most mutagens appear to induce both classes of mutations, with chromosomal mutations (especially multilocus deletions) predominating at high doses. These results have implications regarding the mechanisms of mutagenesis, the role of chromosomal mutations in carcinogenesis and hereditary disease, and the type of data required for risk assessment of physical and chemical mutagens/carcinogens.

Trinitrophenyl reactive T-cell clones in functional and molecular analysis of the HLA-D region

We believe that the approach we have utilized contributes to more complete understanding of the role of HLA class II molecules in presentation of antigen to T lymphocytes and helps to resolve paradoxes presented by earlier studies in which class II-associated restrictions were not apparent. The approach has depended upon development of a library of cloned TCL reactive to a particular haptenic determinant in various class II MHC contexts. It employed initial screening for MHC restriction by analysis on allogeneic stimulator cell panels that could be confirmed or clarified by antibody blocking experiments employing mAb of defined specificities. This has led to clear identification of TCL restricted to recognition of TNP in the context of each of the major class II molecular species, DR, DQ and DP. It has also raised the intriguing and novel possibility that in some instances, at least for DP, T-cells may employ restricting elements, as revealed by mAb blocking, that are either nonpolymorphic or of very low polymorphism. Finally, where important functional polymorphisms have been identified at apparent variance from defined serological specificities, it has been possible to correlate antigen recognition with molecular polymorphisms defined at both the protein level, by amino acid sequencing, and the genomic level by restriction enzyme polymorphisms. As these approaches are combined with new molecular genetic techniques for generation of novel class II constructs, it seems likely that important, but as yet unresolved, questions relating to the nature of the ternary complex involving antigen, MHC molecule and T-cell receptor will be resolved.

Molecular characterization of a subtype of DQw1 recognized by hapten-specific T cells

Previous studies of HLA-restricted antigen recognition by cloned T cells have frequently demonstrated reactivity that did not correlate precisely with the expression of serologically defined HLA specificities. To further explore such discrepancies, we utilized monoclonal antibody (MoAb) blocking, partial NH2-terminal amino acid sequencing, and Southern blot hybridization techniques to analyze the fine specificity of four autologous trinitrophenyl-specific T cell lines restricted to DR2-linked epitopes. MoAb blocking studies demonstrated that two of these lines recognized determinants on DR molecules while the other two recognized determinants on the same molecule that expresses the DQw1 determinant. However, these latter two lines appeared to recognize a DQw1-related determinant found primarily in association with DR2, but not the other DQw1-associated DR alleles, DR1 and DRw6. To ascertain whether these lines were defining a functional split of DQw1, we performed partial NH2-terminal amino acid sequencing of the molecules precipitated with a DQw1-specific MoAb (Genox 3.53) from different stimulator lines. The results showed that these T cell lines recognized a subtype of DQw1 that is in linkage disequilibrium with DR2. Moreover, we identified characteristic restriction fragment length polymorphisms with a DQ beta-specific cDNA that correlated with stimulatory capacity for the DQw1-restricted lines. These results demonstrate that: DQ molecules may provide restriction determinants that are incorrectly assigned to DR molecules on stimulator panel analyses; cloned antigen-specific T cell lines recognize polymorphic regions of class II molecules not distinguished by either conventional typing antisera or xenogeneic MoAb; and the DQw1 epitope(s) is located on a heterogeneous group of DQ molecules that differ from each other in the primary sequence of their beta chains.

NO1: an HLA-DQw1-associated determinant present on loss mutants not expressing DQw1

We have used two monoclonal antibodies, FA and Tu39, and cloned cytotoxic T lymphocytes to study the immunogenetic control of an HLA-D region-encoded determinant(s) recognized by the Tc other than class I or DR or DQ. The Tc recognize a determinant associated with one (the A2) haplotype of LCL721 and are lytic to mutants of LCL 721 that have lost expression of all class I as well as the serologically defined DR and DQw specificities associated with, and presumably identical to, DPw2, the specificity encoded by the sensitizing (A2-B51) haplotype; these data provide the first evidence that FA recognizes the protein dimer presumably expressing the DPw determinant. Those Tc blocked by Tu39 recognized a determinant, referred to as NO1, that is not associated in the population with DPw2, but is found on some, but not all, DQw1-positive cells. We propose three possible explanations for these results. (i) There may be a class II product other than DP or those expressing the DR or DQ serologically defined specificities carrying NO1; such a product could be either as yet undescribed (E. Long has obtained information for an expressed and as yet undefined class II beta gene, personal communication) or a second expressed dimer of the DQ or DP families. (We assume that no DR genes of the A2 haplotype are expressed in these mutants. (ii) NO1 and DPw2 may be on the same molecule; to account for the lack of association of NO1 and DPw2 in the population, one might propose a mechanism such as gene conversion leading to expression of NO1.(ABSTRACT TRUNCATED AT 250 WORDS)

Loss and re-acquisition of lytic function by cloned cytotoxic T lymphocytes: role of specific antigen and interleukin 2

We have previously reported the isolation of 2 human allospecific cytotoxic T-lymphocyte (CTL) clones that can undergo a reversible functional change from a highly lytic phase to a nonlytic quiescent phase and again to a lytic phase. The entire process was found to be regulated by recombinant interleukin 2 (rIL-2). We have now extended these studies in 3 ways. First, we show that specific alloantigens can also function as a signal to reactivate lytic function in the reverted CTL. However, in contrast to CTL reactivated with rIL-2, the antigen-reactivated CTL apparently fail to undergo subsequent cell division. Second, we have also found that this reversion phenomenon is not the same for all CTL tested, as 2 other CTL clones were found that did not revert to the non-lytic phase when cultured for up to 60 h in rIL-2-free medium. Third, the expression of Tac (IL-2 receptor) was also studied throughout the process of reversion and reactivation. rIL-2 added to the cell that had reverted to a non-lytic phase induced, an increase in the expression of Tac receptors during the reactivation phase, to levels greater than those expressed on cells continuously cultured in rIL-2-supplemented medium.

Class II determinants recognized by TNP-specific cloned human T cell lines

Cloned human T lymphocyte lines were generated against trinitrophenyl (TNP)-modified autologous cells from four different individuals. By examining the reactivity patterns of 58 of these T cell clones (TLC) on panels of HLA-typed antigen presenting cells and employing monoclonal antibodies (MoAb) for inhibition studies, we have demonstrated that TNP may be recognized in the context of different DR and DP associated determinants. We did not identify any TLC restricted by determinants associated uniquely with DQ. Determinants associated with the expression of DR1,2,4,5, and 7 as well as the supertypic specificities DRw52 (MT2) and DRw53 (MT3) functioned as restriction elements. In addition, at least two antigenically distinct regions of the DP4 molecule appeared to function in the presentation of TNP. One TNP-specific TLC recognized a determinant associated with the expression of DP4 while another recognized TNP in the context of a highly nonpolymorphic determinant on DP which was expressed on all stimulators tested. Monoclonal antibody blocking studies suggest that these two determinants lie on different portions of the DP molecule. These studies demonstrated that both polymorphic and relatively nonpolymorphic restriction determinants on DR and DP may function in the presentation of conventional antigen to autologous lymphocytes.

A cytolytic human T lymphocyte clone differentially recognizing HLA-B27 subtypes

A cytolytic human T cell (CTL) clone, designated F/M-F159, has been produced, the lytic specificity of which distinguishes subtypes of HLA-B27. This was demonstrated in cell-mediated lympholysis (CML) assays of: 1) a panel of target cells from unrelated donors, 75 B27 + and 36 B27-; 2) six families, including 20 B27 + and 14 B27- individuals; and 3) B27 + and B27- variants of a B27+ lymphoblastoid cell line (LCL). Specificity of F/M-F159 for HLA-B27 was confirmed by blocking studies with monoclonal antibodies. Lysis of B27 + targets reactive with the anti-B27 monoclonal antibody B27M2 was 30-104%, while lysis of B27 +, B27M2- targets was 4-22%. Lysis of B27- targets expressing HLA-Bw47, known to be cross-reactive with the B27M2 antibody, was 10 to 19%, while lysis of all other B27- targets was less than or equal to 10%. Clone F/M-F159 lysed B27 + targets, and failed to lyse B27- targets, irrespective of the clinical status of the cell donors. It is concluded that F/M-F159 recognizes an epitope present on the majority of serologically identified HLA-B27 molecules and that this epitope is closely related to, but not identical with, the epitope recognized by the antibody B27M2. These findings are interpreted as supporting a direct role for HLA-B27 in disease pathogenesis.